Literature DB >> 17961311

Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy.

Noriaki Mitani1, Yoshimasa Niwa, Yasuyuki Okamoto.   

Abstract

BACKGROUND: Surveyor nuclease is a new single-strand-specific endonuclease that cleaves heteroduplex DNA at a base-mismatch site in both DNA strands. We applied this enzyme to detection of p53 gene mutations in haematological malignancy.
METHODS: DNA fragments including exons 5 and 6, and those including exons 7 and 8, of the p53 gene, were amplified by polymerase chain reaction using DNA samples extracted from bone marrow aspirates. Denaturation followed by gradual annealing of the amplified fragments formed a heteroduplex with a base-mismatch if a mutation existed because the DNA samples contained wild-type DNA derived from coexisting non-malignant cells. After cleavage by Surveyor nuclease, mutations were simply detected by gel electrophoresis as extra bands of shorter size.
RESULTS: Somatic mutations were clearly detected by this method in three of 39 different samples and confirmed by sequencing. The limit of detection estimated by changing the proportion of heteroduplexes in hetero/homoduplexes was between 1/8 and 1/16.
CONCLUSION: We suggest that our method is not only simple, but also sensitive, compared with other complicated methods, and would therefore be useful in current clinical laboratory settings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17961311     DOI: 10.1258/000456307782268174

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  9 in total

1.  A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.

Authors:  Ellen Weisberg; Martin Sattler
Journal:  Haematologica       Date:  2012-11       Impact factor: 9.941

Review 2.  Error correction in gene synthesis technology.

Authors:  Siying Ma; Ishtiaq Saaem; Jingdong Tian
Journal:  Trends Biotechnol       Date:  2011-12-28       Impact factor: 19.536

3.  The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.

Authors:  Giorgio Zauli; Claudio Celeghini; Elisabetta Melloni; Rebecca Voltan; Manuele Ongari; Mario Tiribelli; Maria Grazia di Iasio; Francesco Lanza; Paola Secchiero
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

4.  Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines.

Authors:  Claudio Celeghini; Rebecca Voltan; Erika Rimondi; Valter Gattei; Giorgio Zauli
Journal:  Invest New Drugs       Date:  2010-02-04       Impact factor: 3.850

5.  Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo.

Authors:  C Gianna Hoffman-Luca; Daniel Ziazadeh; Donna McEachern; Yujun Zhao; Wei Sun; Laurent Debussche; Shaomeng Wang
Journal:  Clin Cancer Res       Date:  2015-03-09       Impact factor: 12.531

6.  Screening for mutations in kidney-related genes using SURVEYOR nuclease for cleavage at heteroduplex mismatches.

Authors:  Konstantinos Voskarides; Constantinos Deltas
Journal:  J Mol Diagn       Date:  2009-06-12       Impact factor: 5.568

7.  Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors.

Authors:  Irina Mordukhovich; Pavel Rossner; Mary Beth Terry; Regina Santella; Yu-Jing Zhang; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Mia M Gaudet; Susan E Steck; Sharon K Sagiv; Sybil M Eng; Susan L Teitelbaum; Alfred I Neugut; Kathleen Conway-Dorsey; Marilie D Gammon
Journal:  Environ Health Perspect       Date:  2009-11-18       Impact factor: 9.031

8.  Mutations in p53, p53 protein overexpression and breast cancer survival.

Authors:  Pavel Rossner; Marilie D Gammon; Yu-Jing Zhang; Mary Beth Terry; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Tara S Kalra; Mia M Gaudet; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  J Cell Mol Med       Date:  2008-10-16       Impact factor: 5.310

9.  HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.

Authors:  Angela M Sosin; Angelika M Burger; Aisha Siddiqi; Judith Abrams; Ramzi M Mohammad; Ayad M Al-Katib
Journal:  J Hematol Oncol       Date:  2012-09-18       Impact factor: 17.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.